ImmuPharma PLC (LON: IMM), the specialist drug discovery and development company today provides an update on its clinical development collaboration agreement for its Nucant cancer programme, with Incanthera Limited, a specialist oncologd development company.
As announced on 7 December 2018, ImmuPharma alongside Incanthera are making good progress in finalising the ‘Definitive Licence Agreement’. It has been agreed between both companies to extend the exclusivity period, which was initially granted to 31 December 2018, to 31 March 2019, in order to finalise the remaining parts of the agreement.
It is now envisaged that the ‘Definitive Licence Agreement’ will be finalised in the first quarter of 2019 and as such, a further update on this collaboration will be announced in due course.
Commenting, Dimitri Dimitriou, ImmuPharma plc Chief Executive Officer, said:
“We are working diligently with Incanthera’s management team to finalise the last remaining parts to the ‘Definitive Licence Agreement’ and look forward to updating the market and shareholders in Q1 2019.”
Incanthera Limited was formed in 2010 as a spin-out from the Institute of Cancer Therapeutics at Bradford University and is targeting the treatment of cancer through a portfolio of unique technologies. Having successfully commercialised its lead product in 2017, it is actively acquiring technologies to further enhance its portfolio of cancer therapeutics.
